<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70319">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01660841</url>
  </required_header>
  <id_info>
    <org_study_id>16260</org_study_id>
    <nct_id>NCT01660841</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging</brief_title>
  <official_title>A Multicenter, Open-label, Phase III Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects Referred for Contrast-enhanced MRI of the Central Nervous System (CNS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is to look at the safety (what are the side effects) and efficacy (how
      well does it work) of gadobutrol when used for taking images of the brain and spine.  The
      results of the Magnetic Resonance Imaging (MRI) will be compared to the results of images
      taken without contrast (gadobutrol).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Scores for visualization parameter: degree of contrast enhancement</measure>
    <time_frame>Day of gadobutrol injection (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blinded readers evaluate contrast of at maximum 5 lesions  and 4 normal brain structures in scans taken with and without injection of gadobutrol on a 4-point-scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores for visualization parameter: border delineation</measure>
    <time_frame>Day of gadobutrol injection (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blinded readers evaluate border delineation of at maximum 5 lesions and 4 normal brain structures in scans taken with and without injection of gadobutrol on a 4-point-scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores for visualization parameter: internal morphology</measure>
    <time_frame>Day of gadobutrol injection (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blinded readers evaluate internal morphology of at maximum 5 lesions and 4 normal structures in scans taken with and without gadobutrol on a 3-point-scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of detected lesions</measure>
    <time_frame>Day of gadobutrol injection (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blinded readers determine number of detected lesions in scans with and without gadobutrol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of exact match of the MRI diagnosis with the final clinical diagnosis</measure>
    <time_frame>Day of gadobutrol injection (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>An exact match is defined as identical diagnosis given by the blinded reader and the independent standard of truth committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity to detect abnormal/normal brain tissue</measure>
    <time_frame>Day of gadobutrol injection (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blinded readers classify the brain tissue as normal or abnormal based on the MRI sets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity to detect malignant Central Nervous System(CNS) lesions</measure>
    <time_frame>Day of gadobutrol injection (Day 0)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage to correctly detect presence and absence of malignant lesions which are derived from the MR diagnosis of  readers when compared with the diagnosis of the independent standard of truth committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment emergent adverse events as a measure of safety and tolerability</measure>
    <time_frame>3 days after injection (Day 3)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobutrol (Gadovist, BAY86-4875)</intervention_name>
    <description>A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects referred for a contrast-enhanced Magnetic Resonance Imaging (MRI) of the
             central nervous system based on current clinical symptoms or results of a previous
             imaging procedure

        Exclusion Criteria:

          -  Subjects with any contraindication to the MRI examination

          -  Subjects with severe renal disease to end stage renal disease

          -  Subjects scheduled or are likely to require a biopsy or any interventional
             therapeutic procedure within 72 (Â±4) hours after the study MRI
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>455-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Funabashi</city>
        <state>Chiba</state>
        <zip>274-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>800-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuyama</city>
        <state>Hiroshima</state>
        <zip>720-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>654-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <zip>251-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>210-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>226-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daito</city>
        <state>Osaka</state>
        <zip>574-0074</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <zip>596-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimonoseki</city>
        <state>Yamaguchi</state>
        <zip>750-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-0151</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>811-0213</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>810-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 30, 2013</lastchanged_date>
  <firstreceived_date>August 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>central nervous system</keyword>
  <keyword>contrast media</keyword>
  <keyword>gadobutrol</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
